Drugs that contain Buprenorphine Hydrochloride
1. List of Belbuca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
| US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(9 years from now) | |
Market Authorisation Date: 23 October, 2015
Treatment: Treatement of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment option...
Dosage: FILM;BUCCAL
BELBUCA family patents
26
United States
6
Korea, Republic of
5
Australia
4
China
4
New Zealand
4
European Union
3
Israel
3
Hong Kong
3
Russia
3
Norway
3
Singapore
3
Brazil
3
Japan
2
South Africa
2
Mexico
2
Ukraine
2
EA
2
Canada
1
Denmark
1
Slovenia
1
Hungary
1
Croatia
1
Cyprus
1
Spain
1
Poland
1
RS
1
India
2. List of Probuphine drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7736665 | TITAN PHARMS | Implantable polymeric device for sustained release of buprenorphine |
Apr, 2024
(1 year, 23 days from now) | |
Market Authorisation Date: 26 May, 2016
Treatment: For opioid dependence
Dosage: IMPLANT;IMPLANTATION
PROBUPHINE family patents
14
United States
2
Australia
2
European Union
1
Slovenia
1
Japan
1
Hungary
1
Portugal
1
Denmark
1
Cyprus
1
Canada
1
Mexico
1
Spain
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic